2013 Fiscal Year Final Research Report
Studies on the pathogenesis and anti-VEGF treatment of retinopathy of prematurity
| Project/Area Number |
23592597
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
KUSAKA Shunji 近畿大学, 医学部附属病院, 教授 (60260387)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KUNIYOSHI Kazuki 近畿大学, 医学部附属病院, 講師 (30234470)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 未熟児網膜症 / 血管内皮細胞増殖因子 / 血管新生 / 抗体治療 / 抗VEGF治療 |
|---|
| Research Abstract |
Serum samples were collected from 11 infants with ROP who had received intravitreal bevacizumab injection before and 1 day, 1 week, and 2 weeks after the injection. The serum concentrations of bevacizumab and VEGF were measured by enzyme-linked immunosorbent assay. As a result, the serum concentration of bevacizumab before and 1 day, 1week, and 2 weeks after a total of 0.5 mg of intravitreal bevacizumab was 0, 195, 946L, and 1214 (ng/mL), respectively. The serum concentration of VEGF before and 1 day, 1 week, and 2 weeks after a totalof 0.5 mg intravitreal bevacizumab was 1628, 427, 246, and 269 (pg/mL), respectively. There was a significant negative correlation (r= 0.575, P=0.0125) between the serum concentration of bevacizumab and VEGF. These results indicate that bevacizumab can escape from the eye into the systemiccirculation and reduce the serum level of VEGF in infants with ROP.
|
